39 results about "Female contraceptives" patented technology

The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng / ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.

The present invention relates to a method for impairing cumulus expansion and oocyte maturation, the method comprising antagonizing EP2 receptor and / or inhibiting cyclooxygenase COX-2. The invention also relates to the use of a pharmaceutical composition comprising an EP2 receptor antagonist (optionally with one or more COX inhibitors) for female contraception.

A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.

A nasal spray formulation for use in female contraception or in the treatment of benign gynecological disorders is described. The nasal preparation is comprised of a GnRH compound and an estrogenic compound in the form of a water-soluble complex with a water-soluble cyclodextrin. The preparation effectively suppresses ovarian estrogen and progesterone production, and prevents signs and symptoms of estrogen deficiency, without a significant increase in the risk of endometrial hyperplasia.

The present invention provides a method for inducing Fallopian tube blockage as a means for female contraception. The method comprises contacting the inner surface tissue of a Fallopian tube with a silver nitrate bearing substrate, delivering an amount of silver nitrate to the tissue sufficient to induce blockage of the Fallopian tube. Preferably, the substrate is a bead. In one embodiment, at least one silver nitrate bearing bead is introduced through the uterine opening of the Fallopian tube by use of a catheter or other device suitable for manipulating the bead. Alternatively, a plurality of beads can be introduced into the Fallopian tube. In a preferred embodiment, one or more silver nitrate bearing beads are arranged on a string to facilitate later removal of the beads. The method of the present invention delivers an amount of silver nitrate to the tissue sufficient to cause tissue necrosis and blockage of the Fallopian tube. The silver nitrate is delivered to the tissue by the substrate in a controlled and localized manner.

The various embodiments of the present invention provide implantable occlusion devices and methods of using the occlusion devices. In an embodiment, the occlusion devices include an openable channel to facilitate reversible female contraception.

A contraceptive drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a contraceptive agent over an extended time period. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods of using the drug delivery system, including in female contraception, are also provided.

Described are methods for reversible occlusion of a body lumen by way of degradation as a result of exposure to one or more stimuli such as light. The methods include administering one or more substance(s) into a body lumen of a subject and forming a stimuli-responsive polymer mass in the body lumen from the one or more substance(s). The mass is sufficient to occlude the body lumen in a manner that prevents transport of at least one material through the body lumen and is susceptible to on-command reversal in the body lumen upon exposure to one or more stimuli. The methods include administering one or more stimuli to a polymer mass in a body lumen for a time and intensity to cause the reverse the polymer mass. The methods are particular useful for applications in which it is desirable to temporarily occlude a body lumen, such as male and female contraception.

Described are methods for reversible occlusion of a body lumen by way of degradation as a result of exposure to one or more stimuli such as light. The methods include administering one or more substance(s) into a body lumen of a subject and forming a stimuli-responsive polymer mass in the body lumen from the one or more substance(s). The mass is sufficient to occlude the body lumen in a manner that prevents transport of at least one material through the body lumen and is susceptible to on-command reversal in the body lumen upon exposure to one or more stimuli. The methods include administering one or more stimuli to a polymer mass in a body lumen for a time and intensity to cause the reverse the polymer mass. The methods are particular useful for applications in which it is desirable to temporarily occlude a body lumen, such as male and female contraception.

This invention provides, inter alia, commensal organisms engineered to express antibody fragments, which inhibit sperm motility or fertilization and compositions comprising the same. The present invention provides for the use of the engineered commensal organisms or compositions comprising the same as effective contraceptive means in females.

The present invention relates to medical devices and methods for treating and occluding a female patient's fallopian tubes to provide birth control or sterilization, where such birth control / sterilization can be short term, long term, or permanent.

Medical devices and methods for treating and occluding a female patient's fallopian tubes to provide permanent birth control or sterilization.

Methods and devices for treating and occluding a female patient's fallopian tubes to provide permanent or extended birth control or sterilization.

The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng / ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.

The present invention is directed to methods and compositions for use in the diagnosis and treatment of reproductive fertility. More particularly, it is directed to methods and compositions that can be used in male and female contraception and fertility.

Described are methods for reversible occlusion of a body lumen by way of degradation as a result of exposure to one or more stimuli such as light. The methods include administering one or more substance(s) into a body lumen of a subject and forming a stimuli-responsive polymer mass in the body lumen from the one or more substance(s). The mass is sufficient to occlude the body lumen in a manner that prevents transport of at least one material through the body lumen and is susceptible to on-command reversal in the body lumen upon exposure to one or more stimuli. The methods include administering one or more stimuli to a polymer mass in a body lumen for a time and intensity to cause the reverse the polymer mass. The methods are particular useful for applications in which it is desirable to temporarily occlude a body lumen, such as male and female contraception.

Methods and devices for treating and occluding a female patient's fallopian tubes to provide permanent or extended birth control or sterilization.

The invention discloses a female contraceptive patch. The female contraceptive patch comprises a female contraceptive condom body; an open end is arranged on the female contraceptive condom body; a contraceptive patch body integrated with the female contraceptive condom body is arranged outside the female contraceptive condom body; and adhesive sticker is arranged on the inner side of the contraceptive patch body. By the structural design, a user can conveniently wear a contraceptive device when having sexual life, so that the quality of sexual life is guaranteed.

The invention provides an application of lactobacillus crispatus in preparation of female contraceptives. According to the technical scheme, firstly, the influence of lactobacillus crispatus on spermsis studied, and experiments are conducted in an in-vitro co-incubation mode and an animal vaginal administration mode respectively; experimental results show that the lactobacillus crispatus has obvious adhesion to sperms, so that the sperm motility and swimming ability are remarkably reduced. Based on the found new properties of the lactobacillus crispatus, the new application of the lactobacillus crispatus in preparation of female contraceptives is determined. Animal experiments show that when a vaginal suppository containing the lactobacillus crispatus liquid acts on the vagina of a femalemouse, the pregnancy rate of the female mouse can be accurately reduced, and the contraceptive rate can reach about 50%. A lactobacillus crispatus bacterial suspension is safe and non-toxic, the probiotic effect of the lactobacillus crispatus bacterial suspension is combined with reproductive contraception, the limitation of a traditional contraception mode is broken through, and the lactobacillus crispatus bacterial suspension is safe, effective and reversible, can help to adjust genital tract micro-ecological balance of women and is of great significance to reproductive health of women.

Medical devices and methods for treating and occluding a female patient's fallopian tubes to provide permanent birth control or sterilization.

A contraceptive drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a contraceptive agent over an extended time period. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods of using the drug delivery system, including in female contraception, are also provided.

The various embodiments of the present invention provide implantable occlusion devices and methods of using the occlusion devices. In an embodiment, the occlusion devices include an openable channel to facilitate reversible female contraception.

Devices and methods for accessing a female patient's fallopian tubes.

The invention belongs to the biotechnical field, and relates to an immunogen for preparing an LRRC52 polyclonal antibody. The immunogen is a polypeptide, and the amino acid sequence of the immunogen is CQNNRIREVMDYTFI. The LRRC52 polyclonal antibody prepared by using the immunogen has the advantages of high titer and good specificity. The antibody can substantially inhibit the generation of sperm potassium current after incubated with mouse or human sperms in order to substantially influence the physiologic functions of mouse and human mature sperms. The antibody can be used for researching the physiologic adjusting mechanism of the sperms as a tool medicine, and can also be used for developing novel female contraceptives as a candidate molecule.

The invention discloses the application of sanguinarine and its salt as external spermicide for women. Its notable feature is that it can kill sperm quickly with low concentration, and it is cheap, safe and reliable. The minimum spermicidal concentration of sanguinarine aqueous solution (pH=4.5) was 0.25 mg / L for 20 seconds, and 0.15 mg / L for 3 minutes. The low spermicidal concentration in the anti-fertility test was 0.5 mg / kg with an ED50 value of 0.129 mg / kg. Compared with the commonly used nonoxynol, sanguinarine has better spermicidal indicators than nonoxynol, and it is expected to become a new type of high-efficiency external contraceptive for women.

The invention belongs to the biotechnical field, and relates to an immunogen for preparing an LRRC52 polyclonal antibody. The immunogen is a polypeptide, and the amino acid sequence of the immunogen is CQNNRIREVMDYTFI. The LRRC52 polyclonal antibody prepared by using the immunogen has the advantages of high titer and good specificity. The antibody can substantially inhibit the generation of sperm potassium current after incubated with mouse or human sperms in order to substantially influence the physiologic functions of mouse and human mature sperms. The antibody can be used for researching the physiologic adjusting mechanism of the sperms as a tool medicine, and can also be used for developing novel female contraceptives as a candidate molecule.

Disclosed herein are compositions and methods for controlling fertility of a female subject. Particularly exemplified are compositions comprising sugar derivatives, such as 2-deoxyglucose, D-mannoheptulose; and / or 5-thio-D-glucose. Also disclosed herein are methods of preserving ova supply in a female subject that involves administering glucose derivatives. The composition typically includes a glucose derivative that affects Foxo3a expression.